Try the Demo today!
| SEC Filing | Company/Stock | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Gain/Loss |
|---|---|---|---|---|---|---|---|---|
| 09-Apr-24 6:38 PM View:  | Omniab, Inc. (OABI) | 07-Apr-24 | Payment of Exercise | 18,477 | $5.31 | $98,112.90 | (< 1%) 3.19M to 3.17M | |
| 09-Apr-24 6:38 PM View: | Omniab, Inc. (OABI) | 07-Apr-24 | Option Exercise | 36,458 | -- | -- | 1% 3.15M to 3.19M | |
| 29-Mar-24 4:52 PM View: | Omniab, Inc. (OABI) | 27-Mar-24 | Option Exercise | 243,613 | $3.72 | $907,023.00 | 8% 2.91M to 3.15M | |
| 25-Mar-24 7:07 AM View: | Omniab, Inc. (OABI) | 22-Mar-24 | Purchase | 225,000 | $5.19 | $1,167,750.00 | 8% 2.68M to 2.91M | |
| 20-Feb-24 6:22 PM View: | Omniab, Inc. (OABI) | 15-Feb-24 | Payment of Exercise | 18,919 | $5.54 | $104,811.00 | (< 1%) 2.7M to 2.68M | |
| 20-Feb-24 6:22 PM View: | Omniab, Inc. (OABI) | 15-Feb-24 | Option Exercise | 37,328 | -- | -- | 1% 2.67M to 2.7M | |
| 03-Jan-24 5:42 PM View: | Omniab, Inc. (OABI) | 02-Jan-24 | Payment of Exercise | 13,221 | $6.25 | $82,631.20 | (< 1%) 2.68M to 2.67M | |
| 03-Jan-24 5:42 PM View: | Omniab, Inc. (OABI) | 02-Jan-24 | Option Exercise | 33,173 | -- | -- | 1% 2.65M to 2.68M | |
| 13-Dec-23 3:25 PM View: | Omniab, Inc. (OABI) | 12-Dec-23 | Purchase | 200,000 | $5.05 | $1,010,000.00 | 8% 2.45M to 2.65M | |
| 11-Dec-23 7:24 PM View: | Omniab, Inc. (OABI) | 07-Dec-23 | Payment of Exercise | 9,184 | $4.85 | $44,542.40 | (< 1%) 2.45M to 2.45M | |
| 11-Dec-23 7:24 PM View: | Omniab, Inc. (OABI) | 07-Dec-23 | Option Exercise | 26,556 | -- | -- | 1% 2.43M to 2.45M | |
| 13-Nov-23 8:00 AM View: | Omniab, Inc. (OABI) | 10-Nov-23 | Purchase | 95,000 | $4.27 | $405,517.00 | 4% 2.33M to 2.43M | |
| 15-Aug-23 4:56 PM View: | Omniab, Inc. (OABI) | 14-Aug-23 | Purchase | 45,000 | $5.48 | $246,600.00 | 2% 2.29M to 2.33M | |
| 12-Jun-23 4:47 PM View: | Omniab, Inc. (OABI) | 09-Jun-23 | Purchase | 115,000 | $4.52 | $519,800.00 | 5% 2.46M to 2.57M | |
| 15-May-23 4:02 PM View: | Omniab, Inc. (OABI) | 12-May-23 | Purchase | 440,000 | $3.40 | $1,496,000.00 | 22% 2.0M to 2.44M | |
| 11-Apr-23 7:11 PM View: | Omniab, Inc. (OABI) | 07-Apr-23 | Grant | 109,375 | -- | -- | 6% 1.89M to 2.0M | |
| 17-Feb-23 7:28 PM View: | Omniab, Inc. (OABI) | 15-Feb-23 | Payment of Exercise | 17,086 | $3.80 | $64,926.80 | (< 1%) 1.91M to 1.89M | |
| 05-Jan-23 5:05 PM View: | Omniab, Inc. (OABI) | 03-Jan-23 | Grant | 79,665 | -- | -- | 4% 1.83M to 1.91M | |
| 30-Dec-22 5:00 PM View: | Omniab, Inc. (OABI) | 28-Dec-22 | Payment of Exercise | 11,624 | $3.66 | $42,543.80 | (< 1%) 1.84M to 1.83M | |
| 14-Dec-22 5:00 PM View: | Omniab, Inc. (OABI) | 12-Dec-22 | Purchase | 150,000 | $3.77 | $564,765.00 | 9% 1.69M to 1.84M | |
| 05-Dec-22 9:36 PM View: | Omniab, Inc. (OABI) | 01-Dec-22 | Payment of Exercise | 17,266 | $3.35 | $57,841.10 | (1%) 1.71M to 1.69M | |
| 01-Dec-22 6:00 PM View: | Omniab, Inc. (OABI) | 30-Nov-22 | Purchase | 300,000 | $3.39 | $1,016,340.00 | 21% 1.41M to 1.71M | |
| 09-Nov-22 8:30 PM View: | Omniab, Inc. (OABI) | 09-Nov-22 | Purchase | 100,000 | $2.76 | $276,160.00 | 8% 1.31M to 1.41M | |
| 03-Nov-22 9:10 PM View: | Omniab, Inc. (OABI) | 01-Nov-22 | Grant | 1,305,350 | -- | -- | 100% 0 to 1.31M | |
| 03-Nov-22 9:10 PM View: | Omniab, Inc. (NONE) | 01-Nov-22 | Grant | 26,193 | -- | -- | 14% 186.17K to 212.36K | |
| 03-Nov-22 9:10 PM View: | Omniab, Inc. (NONE) | 01-Nov-22 | Disposition | 212,362 | -- | -- | (100%) 212.36K to 0 | |
| 03-Nov-22 9:06 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 01-Nov-22 | Disposition | 20,304 | -- | -- | (11%) 182.49K to 162.19K | |
| 14-Jun-22 5:55 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 10-Jun-22 | Grant | 9,137 | -- | -- | 5% 173.35K to 182.49K | |
| 13-May-22 7:05 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 13-May-22 | Private Purchase | 2,500 | $82.76 | $206,910.00 | 1% 170.85K to 173.35K | |
| 03-May-22 4:12 PM View: | Viking Therapeutics, Inc. (VKTX) | 02-May-22 | Private Purchase | 45,000 | $2.47 | $111,195.00 | 68% 66.25K to 111.25K | |
| 16-Feb-22 8:24 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 15-Feb-22 | Payment of Exercise | 3,546 | $123.68 | $438,569.00 | (2%) 174.4K to 170.85K | |
| 28-Jan-22 8:41 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 26-Jan-22 | Grant | 13,000 | -- | -- | 8% 166.53K to 179.53K | |
| 28-Jan-22 8:41 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 26-Jan-22 | Payment of Exercise | 5,125 | $113.68 | $582,610.00 | (3%) 179.53K to 174.4K | |
| 12-Nov-21 4:54 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 11-Nov-21 | Option Exercise | 12,188 | $28.54 | $347,818.00 | 7% 165.5K to 177.69K | |
| 12-Nov-21 4:54 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 11-Nov-21 | Market Option Sale | 11,160 | $163.02 | $1,819,260.00 | (6%) 177.69K to 166.53K | |
| 10-Jun-21 4:57 PM View: | Viking Therapeutics, Inc. (VKTX) | 10-Jun-21 | Market Purchase | 20,000 | $5.69 | $113,800.00 | 43% 46.25K to 66.25K | (2%) |
| 01-Jun-21 4:59 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 28-May-21 | Gift | 2,500 | -- | -- | (1%) 166.85K to 164.35K | |
| 01-Jun-21 4:59 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 28-May-21 | Option Exercise | 1,755 | $56.26 | $98,736.30 | 1% 165.1K to 166.85K | |
| 25-Mar-21 9:30 PM View: | Viking Therapeutics, Inc. (VKTX) | 22-Mar-21 | Exercise (in-the money or at-the-money) | 20,000 | $1.50 | $30,000.00 | 76% 26.25K to 46.25K | |
| 18-Feb-21 6:28 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 15-Feb-21 | Payment of Exercise | 3,098 | $172.46 | $534,281.00 | (2%) 168.2K to 165.1K | 25% |
| 05-Feb-21 5:03 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 04-Feb-21 | Option Exercise | 45,547 | $23.07 | $1,050,890.00 | 27% 167.2K to 212.75K | |
| 05-Feb-21 5:03 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 04-Feb-21 | Market Option Sale | 44,547 | $176.86 | $7,878,580.00 | (21%) 212.75K to 168.2K | 27% |
| 05-Feb-21 5:03 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 03-Feb-21 | Grant | 6,595 | -- | -- | 4% 160.6K to 167.2K | |
| 27-Jan-21 7:03 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 25-Jan-21 | Grant | 8,515 | -- | -- | 5% 155.41K to 163.93K | |
| 27-Jan-21 7:03 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 25-Jan-21 | Payment of Exercise | 3,325 | $156.01 | $518,733.00 | (2%) 163.93K to 160.6K | 17% |
| 25-Aug-20 7:10 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 24-Aug-20 | Option Exercise | 78 | $21.92 | $1,709.76 | < 1% 155.41K to 155.49K | |
| 25-Aug-20 7:10 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 24-Aug-20 | Market Option Sale (Planned) | 78 | $110.89 | $8,649.42 | (< 1%) 155.49K to 155.41K | (17%) |
| 25-Aug-20 7:10 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 21-Aug-20 | Option Exercise | 790 | $74.42 | $58,791.80 | < 1% 154.62K to 155.41K | |
| 25-Aug-20 7:10 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 21-Aug-20 | Option Exercise | 7,225 | $14.47 | $104,546.00 | 5% 155.41K to 162.64K | |
| 25-Aug-20 7:10 PM View: | Ligand Pharmaceuticals Inc. (LGND) | 21-Aug-20 | Market Option Sale (Planned) | 7,225 | $112.88 | $815,541.00 | (4%) 162.64K to 155.41K | (15%) |